US-based biotechnology company Toragen has reported positive safety outcomes from a Phase I trial of TGN-S11, its small molecule drug candidate for the treatment of human papillomavirus (HPV) related cancers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,